{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T07:20:28Z","timestamp":1781594428834,"version":"3.54.5"},"reference-count":92,"publisher":"MDPI AG","issue":"9","license":[{"start":{"date-parts":[[2021,4,28]],"date-time":"2021-04-28T00:00:00Z","timestamp":1619568000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Acute kidney injury is a common complication of many medical procedures, including those used in cancer treatment. Both chemotherapy and immunotherapy may result in deterioration of kidney function, which may lead to an increase in mortality among patients with cancer. Antineoplastic agents can affect any element of the nephron, leading to the appearance of clinical symptoms such as proteinuria, hypertension, electrolyte disorders, glomerulonephritis, acute and chronic interstitial nephritis and acute kidney injury. The medical literature describing renal complications occurring during chemotherapeutic and immunotherapeutic treatment in neoplasms, such as colorectal cancer, non-small cell lung cancer and melanoma, was analysed. The immune system plays an important role in controlling the development of neoplasms and fighting them. Oncological treatment algorithms include immunotherapy as monotherapy, combined with chemotherapy or chemotherapy as monotherapy. In the treatment of the above-mentioned neoplasms immunotherapeutics are used, such as checkpoint inhibitors (CPI) (i.e., ipilimumab, pembrolizumab, nivolumab, atezolizumab), vascular endothelial growth factor (VEGF) inhibitors (i.e., bevacizumab, ramucirumab) and a variety of chemotherapeutic agents (irinotecan, capecitabine, oxaliplatin, gefitinib, erlotinib, gemcitabine, cisplatin, paclitaxel, carboplatin, doclitaxel, vinorelbine, topotecan, etoposide). In our article, we focused on the number and type of renal complications as well as on the time of their manifestation when using specific treatment regimens. Our analysis also includes case reports. We discussed treatment of immunological complications and adjustments of the dose of chemotherapeutic agents depending on the creatinine clearance. Analysing the data from the literature, when two immunotherapeutic agents are used together, the number of recorded renal complications increases. Bevacizumab and ramucirumab are the cause of the largest number of renal complications among the immunotherapeutic agents described above. Cisplatin is the best-described substance with the greatest nephrotoxic potential among the chemotherapeutic agents. Crucial for renal complications are also cancer stage, previous chemotherapy and other risk factors of AKI such as age, comorbidities and medications used. Due to the described complications during oncological treatment, including kidney damage, it seems necessary to elaborate standards of cooperation between oncologists and nephrologists both during and after treatment of a patient with cancer. Therefore, it is necessary to conduct further research and develop algorithms for management of a cancer patient, especially during such an intensive progress in oncology.<\/jats:p>","DOI":"10.3390\/ijms22094618","type":"journal-article","created":{"date-parts":[[2021,4,28]],"date-time":"2021-04-28T10:41:58Z","timestamp":1619606518000},"page":"4618","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":64,"title":["Nephrotoxicity as a Complication of Chemotherapy and Immunotherapy in the Treatment of Colorectal Cancer, Melanoma and Non-Small Cell Lung Cancer"],"prefix":"10.3390","volume":"22","author":[{"given":"Joanna","family":"Jagie\u0142a","sequence":"first","affiliation":[{"name":"Department of Nephrology, Hypertension and Family Medicine, Medical University of \u0141\u00f3d\u017a, \u017beromskiego 113, 90-549 \u0141\u00f3d\u017a, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Piotr","family":"Bartnicki","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Hypertension and Family Medicine, Medical University of \u0141\u00f3d\u017a, \u017beromskiego 113, 90-549 \u0141\u00f3d\u017a, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacek","family":"Rysz","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Hypertension and Family Medicine, Medical University of \u0141\u00f3d\u017a, \u017beromskiego 113, 90-549 \u0141\u00f3d\u017a, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2021,4,28]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.2215\/CJN.02050309","article-title":"Renal vulnerability to drug toxicity","volume":"4","author":"Perazella","year":"2009","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1080\/07853890510007205","article-title":"Acute renal failure in cancer patients","volume":"37","author":"Lameire","year":"2005","journal-title":"Ann. Med."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1681\/ASN.2004100843","article-title":"Renal failure associated with cancer and its treatment: An update","volume":"16","author":"Humphreys","year":"2005","journal-title":"J. Am. Soc. Nephrol."},{"key":"ref_4","unstructured":"(2021, March 30). National Cancer Institute, Available online: https:\/\/ctep.cancer.gov\/protocoldevelopment\/electronic_applications\/ctc.htm."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1974","DOI":"10.1200\/JCO.2014.59.4358","article-title":"Immune Checkpoint Blockade in Cancer Therapy","volume":"33","author":"Postow","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"190","DOI":"10.5306\/wjco.v11.i4.190","article-title":"Nephrotoxicity in cancer treatment: An overview","volume":"11","author":"Santos","year":"2020","journal-title":"World J. Clin. Oncol"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"3479","DOI":"10.18632\/oncotarget.2980","article-title":"PD-1 pathway inhibitors: The next generation of immunotherapy for advanced melanoma","volume":"6","author":"Luke","year":"2015","journal-title":"Oncotarget"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1038\/nrc3239","article-title":"The blockade of immune checkpoints in cancer immunotherapy","volume":"12","author":"Pardoll","year":"2012","journal-title":"Nat. Rev. Cancer"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1007\/s00262-015-1677-5","article-title":"Novel strategies for inhibiting PD-1 pathway-mediated immune suppression while simultaneously delivering activating signals to tumor-reactive T cells","volume":"64","author":"Horn","year":"2015","journal-title":"Cancer Immunol. Immunother."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"a006593","DOI":"10.1101\/cshperspect.a006593","article-title":"The VEGF pathway in cancer and disease: Responses, resistance, and the path forward","volume":"2","author":"Kieran","year":"2012","journal-title":"Cold Spring Harb. Perspect. Med."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1677","DOI":"10.1093\/annonc\/mdv136","article-title":"Renal effects of molecular targeted therapies in oncology: A review by the Cancer and the Kidney International Network (C-KIN)","volume":"26","author":"Aapro","year":"2015","journal-title":"Ann. Oncol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1002\/1878-0261.12155","article-title":"Emerging functions of the EGFR in cancer","volume":"12","author":"Sigismund","year":"2018","journal-title":"Mol. Oncol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1158\/1541-7786.MCR-06-0404","article-title":"The Role of VEGF and EGFR Inhibition: Implications for Combining Anti\u2013VEGF and Anti\u2013EGFR Agents","volume":"5","author":"Tabernero","year":"2007","journal-title":"Mol. Cancer Res."},{"key":"ref_14","doi-asserted-by":"crossref","unstructured":"Miyamoto, Y., Suyama, K., and Baba, H. (2017). Recent Advances in Targeting the EGFR Signaling Pathway for the Treatment of Metastatic Colorectal Cancer. Int. J. Mol. Sci., 18.","DOI":"10.3390\/ijms18040752"},{"key":"ref_15","first-page":"1005","article-title":"Melanoma: Epidemiology, Risk Factors, Pathogenesis, Diagnosis and Classification","volume":"28","author":"Rastrelli","year":"2014","journal-title":"In Vivo"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"35","DOI":"10.2147\/ITT.S134842","article-title":"Melanoma treatment in review","volume":"7","author":"Domingues","year":"2018","journal-title":"Immunotargets Ther."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1056\/NEJMoa1412082","article-title":"Nivolumab in Previously Untreated Melanoma without BRAF Mutation","volume":"372","author":"Robert","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1200\/JCO.2013.53.0105","article-title":"Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab","volume":"32","author":"Topalian","year":"2014","journal-title":"J. Clin. Oncol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/s40425-016-0205-2","article-title":"Interstitial nephritis in melanoma patients secondary to PD-1 checkpoint inhibitor","volume":"5","author":"Escandon","year":"2017","journal-title":"J. Immunother. Cancer"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/S1470-2045(15)70076-8","article-title":"Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): A randomised, controlled, open-label, phase 3 trial","volume":"16","author":"Weber","year":"2015","journal-title":"Lancet Oncol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1744","DOI":"10.1001\/jama.2014.13943","article-title":"Ipilimumab plus sargramostim vs ipilimumab alone for treatment of metastatic melanoma: A randomized clinical trial","volume":"312","author":"Hodi","year":"2014","journal-title":"JAMA"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1457","DOI":"10.1038\/bjc.2016.358","article-title":"Acute interstitial nephritis related to immune checkpoint inhibitors","volume":"115","author":"Belliere","year":"2016","journal-title":"Br. J. Cancer"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"3815","DOI":"10.1200\/JCO.2016.72.1167","article-title":"Pooled Analysis Safety Profile of Nivolumab and Ipilimumab Combination Therapy in Patients with Advanced Melanoma","volume":"35","author":"Sznol","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1093\/ckj\/sfw024","article-title":"Severe acute interstitial nephritis after combination immune-checkpoint inhibitor therapy for metastatic melanoma","volume":"9","author":"Murakami","year":"2016","journal-title":"Clin. Kidney J."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1016\/S1470-2045(15)00083-2","article-title":"Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): A randomised, controlled, phase 2 trial","volume":"16","author":"Ribas","year":"2015","journal-title":"Lancet Oncol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"2521","DOI":"10.1056\/NEJMoa1503093","article-title":"Pembrolizumab versus Ipilimumab in Advanced Melanoma","volume":"372","author":"Robert","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1093\/ckj\/sfy100","article-title":"Renal toxicities associated with pembrolizumab","volume":"12","author":"Izzedine","year":"2018","journal-title":"Clin. Kidney J."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1016\/S0025-6196(11)60735-0","article-title":"Non-small cell lung cancer: Epidemiology, risk factors, treatment, and survivorship","volume":"83","author":"Molina","year":"2008","journal-title":"Mayo Clin. Proc."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1623","DOI":"10.1016\/j.mayocp.2019.01.013","article-title":"Non-Small Cell Lung Cancer: Epidemiology, Screening, Diagnosis, and Treatment","volume":"94","author":"Duma","year":"2019","journal-title":"Mayo Clin. Proc."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"e10","DOI":"10.4110\/in.2020.20.e10","article-title":"Immunotherapy for Non-small Cell Lung Cancer: Current Landscape and Future Perspectives","volume":"20","author":"Lim","year":"2020","journal-title":"Immune Netw."},{"key":"ref_31","first-page":"259","article-title":"Bevacizumab in the treatment of NSCLC: Patient selection and perspectives","volume":"8","author":"Russo","year":"2017","journal-title":"Lung Cancer"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"2004","DOI":"10.1200\/JCO.2014.58.3708","article-title":"Overall Survival and Long-Term Safety of Nivolumab (Anti-Programmed Death 1 Antibody, BMS-936558, ONO-4538) in Patients with Previously Treated Advanced Non-Small-Cell Lung Cancer","volume":"33","author":"Gettinger","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/S1470-2045(15)70054-9","article-title":"Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): A phase 2, single-arm trial","volume":"16","author":"Rizvi","year":"2015","journal-title":"Lancet Oncol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1056\/NEJMoa1504627","article-title":"Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer","volume":"373","author":"Brahmer","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"2415","DOI":"10.1056\/NEJMoa1613493","article-title":"First-Line Nivolumab in Stage IV or Recurrent Non-Small-Cell Lung Cancer","volume":"376","author":"Carbone","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"e0195945","DOI":"10.1371\/journal.pone.0195945","article-title":"Clinical factors associated with early progression and grade 3-4 toxicity in patients with advanced non-small-cell lung cancers treated with nivolumab","volume":"13","author":"Dumenil","year":"2018","journal-title":"PLoS ONE"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1056\/NEJMoa1507643","article-title":"Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer","volume":"373","author":"Borghaei","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"3135","DOI":"10.2169\/internalmedicine.0444-17","article-title":"The Analysis of Renal Infiltrating Cells in Acute Tubulointerstitial Nephritis Induced by Anti-PD-1 Antibodies: A Case Report and Review of the Literature","volume":"57","author":"Tabei","year":"2018","journal-title":"Intern. Med."},{"key":"ref_39","doi-asserted-by":"crossref","unstructured":"Koda, R., Watanabe, H., Tsuchida, M., Iino, N., Suzuki, K., Hasegawa, G., Imai, N., and Narita, I. (2018). Immune checkpoint inhibitor (nivolumab)-associated kidney injury and the importance of recognizing concomitant medications known to cause acute tubulointerstitial nephritis: A case report. BMC Nephrol., 19.","DOI":"10.1186\/s12882-018-0848-y"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"2018","DOI":"10.1056\/NEJMoa1501824","article-title":"Pembrolizumab for the Treatment of Non\u2013Small-Cell Lung Cancer","volume":"372","author":"Garon","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.1056\/NEJMoa1606774","article-title":"Pembrolizumab versus Chemotherapy for PD-L1\u2013Positive Non\u2013Small-Cell Lung Cancer","volume":"375","author":"Reck","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"1819","DOI":"10.1016\/S0140-6736(18)32409-7","article-title":"Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): A randomised, open-label, controlled, phase 3 trial","volume":"393","author":"Mok","year":"2019","journal-title":"Lancet"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"2078","DOI":"10.1056\/NEJMoa1801005","article-title":"Pembrolizumab plus Chemotherapy in Metastatic Non\u2013Small-Cell Lung Cancer","volume":"378","author":"Gandhi","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"977","DOI":"10.2169\/internalmedicine.3928-19","article-title":"Renal Effects after Pembrolizumab Treatment for Non-small Cell Lung Carcinoma","volume":"59","author":"Oki","year":"2020","journal-title":"Intern. Med."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"2544","DOI":"10.1200\/JCO.2005.02.477","article-title":"Phase I\/II Trial Evaluating the Anti-Vascular Endothelial Growth Factor Monoclonal Antibody Bevacizumab in Combination With the HER-1\/Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Erlotinib for Patients With Recurrent Non\u2013Small-Cell Lung Cancer","volume":"23","author":"Herbst","year":"2005","journal-title":"J. Clin. Oncol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"2184","DOI":"10.1200\/JCO.2004.11.022","article-title":"Randomized Phase II Trial Comparing Bevacizumab Plus Carboplatin and Paclitaxel with Carboplatin and Paclitaxel Alone in Previously Untreated Locally Advanced or Metastatic Non-Small-Cell Lung Cancer","volume":"22","author":"Johnson","year":"2004","journal-title":"J. Clin. Oncol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"2542","DOI":"10.1056\/NEJMoa061884","article-title":"Paclitaxel\u2013Carboplatin Alone or with Bevacizumab for Non\u2013Small-Cell Lung Cancer","volume":"355","author":"Sandler","year":"2006","journal-title":"N. Engl. J. Med."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1016\/j.lungcan.2011.12.005","article-title":"Randomized phase II study of first-line carboplatin-paclitaxel with or without bevacizumab in Japanese patients with advanced non-squamous non-small-cell lung cancer","volume":"76","author":"Niho","year":"2012","journal-title":"Lung Cancer"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"2197","DOI":"10.1200\/JCO.2014.59.4424","article-title":"BEYOND: A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Phase III Study of First-Line Carboplatin\/Paclitaxel Plus Bevacizumab or Placebo in Chinese Patients With Advanced or Recurrent Nonsquamous Non\u2013Small-Cell Lung Cancer","volume":"33","author":"Zhou","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"3284","DOI":"10.1200\/JCO.2008.20.8181","article-title":"Phase II Study of Pemetrexed and Carboplatin Plus Bevacizumab with Maintenance Pemetrexed and Bevacizumab As First-Line Therapy for Nonsquamous Non\u2013Small-Cell Lung Cancer","volume":"27","author":"Patel","year":"2009","journal-title":"J. Clin. Oncol."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1200\/JCO.2007.14.5466","article-title":"Phase III Trial of Cisplatin Plus Gemcitabine with Either Placebo or Bevacizumab As First-Line Therapy for Nonsquamous Non\u2013Small-Cell Lung Cancer: AVAiL","volume":"27","author":"Reck","year":"2009","journal-title":"J. Clin. Oncol."},{"key":"ref_52","first-page":"89","article-title":"Epidemiology of colorectal cancer: Incidence, mortality, survival, and risk factors","volume":"14","author":"Rawla","year":"2019","journal-title":"Przeglad Gastroenterologiczny"},{"key":"ref_53","first-page":"105","article-title":"Epidemiology of colorectal cancer","volume":"7","author":"Marley","year":"2016","journal-title":"Int J. Mol. Epidemiol. Genet."},{"key":"ref_54","doi-asserted-by":"crossref","unstructured":"Golshani, G., and Zhang, Y. (2020). Advances in immunotherapy for colorectal cancer: A review. Therap. Adv. Gastroenterol., 13.","DOI":"10.1177\/1756284820917527"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1016\/S1470-2045(17)30422-9","article-title":"Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): An open-label, multicentre, phase 2 study","volume":"18","author":"Overman","year":"2017","journal-title":"Lancet Oncol."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1200\/JCO.2017.76.9901","article-title":"Durable Clinical Benefit with Nivolumab Plus Ipilimumab in DNA Mismatch Repair\u2013Deficient\/Microsatellite Instability\u2013High Metastatic Colorectal Cancer","volume":"36","author":"Overman","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1016\/S1470-2045(15)70127-0","article-title":"Ramucirumab versus placebo in combination with second-line FOLFIRI in patients with metastatic colorectal carcinoma that progressed during or after first-line therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine (RAISE): A randomised, double-blind, multicentre, phase 3 study","volume":"16","author":"Tabernero","year":"2015","journal-title":"Lancet Oncol."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"2082","DOI":"10.1093\/annonc\/mdw402","article-title":"Subgroup analysis in RAISE: A randomized, double-blind phase III study of irinotecan, folinic acid, and 5-fluorouracil (FOLFIRI) plus ramucirumab or placebo in patients with metastatic colorectal carcinoma progression","volume":"27","author":"Yoshino","year":"2016","journal-title":"Ann. Oncol. Off. J. Eur. Soc. Med. Oncol."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"3697","DOI":"10.1200\/JCO.2005.05.112","article-title":"Addition of Bevacizumab to Bolus Fluorouracil and Leucovorin in First-Line Metastatic Colorectal Cancer: Results of a Randomized Phase II Trial","volume":"23","author":"Kabbinavar","year":"2005","journal-title":"J. Clin. Oncol."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1186\/1471-2407-7-91","article-title":"Front-line bevacizumab in combination with oxaliplatin, leucovorin and 5-fluorouracil (FOLFOX) in patients with metastatic colorectal cancer: A multicenter phase II study","volume":"7","author":"Emmanouilides","year":"2007","journal-title":"BMC Cancer"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"2335","DOI":"10.1056\/NEJMoa032691","article-title":"Bevacizumab plus Irinotecan, Fluorouracil, and Leucovorin for Metastatic Colorectal Cancer","volume":"350","author":"Hurwitz","year":"2004","journal-title":"N. Engl. J. Med."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"2013","DOI":"10.1200\/JCO.2007.14.9930","article-title":"Bevacizumab in Combination with Oxaliplatin-Based Chemotherapy as First-Line Therapy in Metastatic Colorectal Cancer: A Randomized Phase III Study","volume":"26","author":"Saltz","year":"2008","journal-title":"J. Clin. Oncol."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"8643","DOI":"10.1158\/0008-5472.CAN-07-6611","article-title":"A History of Cancer Chemotherapy","volume":"68","author":"DeVita","year":"2008","journal-title":"Cancer Res."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"1376","DOI":"10.1002\/cncr.22904","article-title":"Prevalence of Renal Insufficiency in cancer patients and implications for anticancer drug management: The renal insufficiency and anticancer medications (IRMA) study","volume":"110","author":"Oudard","year":"2007","journal-title":"Cancer"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1200\/JOP.2016.017210","article-title":"Adjuvant Chemotherapy for Stage II Colon Cancer: A Clinical Dilemma","volume":"13","author":"Kannarkatt","year":"2017","journal-title":"J. Oncol. Pract."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1002\/1097-0142(20010215)91:4<704::AID-CNCR1055>3.0.CO;2-2","article-title":"Phase II study of irinotecan as first-line chemotherapy for patients with advanced colorectal carcinoma","volume":"91","author":"Irigoyen","year":"2001","journal-title":"Cancer"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1200\/JCO.2006.08.3675","article-title":"Multicenter Phase II Trial of Chemoradiation with Oxaliplatin for Rectal Cancer","volume":"25","author":"Liersch","year":"2007","journal-title":"J. Clin. Oncol."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1038\/sj.bjc.6603645","article-title":"A phase II study of capecitabine and irinotecan in combination with concurrent pelvic radiotherapy (CapIri-RT) as neoadjuvant treatment of locally advanced rectal cancer","volume":"96","author":"Willeke","year":"2007","journal-title":"Br. J. Cancer"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"5335","DOI":"10.1200\/JCO.2008.16.3758","article-title":"Cetuximab Plus Irinotecan in Heavily Pretreated Metastatic Colorectal Cancer Progressing on Irinotecan: MABEL Study","volume":"26","author":"Wilke","year":"2008","journal-title":"J. Clin. Oncol."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1093\/annonc\/mdf089","article-title":"First-line oral capecitabine therapy in metastatic colorectal cancer: A favorable safety profile compared with intravenous 5-fluorouracil\/leucovorin","volume":"13","author":"Cassidy","year":"2002","journal-title":"Ann. Oncol."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1186\/1472-6904-6-5","article-title":"Hemolytic uremic syndrome following the infusion of oxaliplatin: Case report","volume":"6","author":"Dahabreh","year":"2006","journal-title":"BMC Clin. Pharmacol."},{"key":"ref_72","first-page":"254","article-title":"Oxaliplatin-induced acute renal failure presenting clinically as thrombotic microangiopathy: Think of acute tubular necrosis","volume":"2","author":"Phan","year":"2009","journal-title":"NDT Plus"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"1","DOI":"10.5306\/wjco.v8.i1.1","article-title":"Therapeutic management options for stage III non-small cell lung cancer","volume":"8","author":"Yoon","year":"2017","journal-title":"World J. Clin. Oncol."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"iv1","DOI":"10.1093\/annonc\/mdx222","article-title":"Early and locally advanced non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"28","author":"Postmus","year":"2017","journal-title":"Ann. Oncol."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1007\/s12094-019-02134-7","article-title":"Multidisciplinary consensus statement on the clinical management of patients with stage III non-small cell lung cancer","volume":"22","author":"Majem","year":"2020","journal-title":"Clin. Transl. Oncol."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1038\/sj.bjc.6603393","article-title":"A phase II trial of gefitinib as first-line therapy for advanced non-small cell lung cancer with epidermal growth factor receptor mutations","volume":"95","author":"Asahina","year":"2006","journal-title":"Br. J. Cancer"},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1038\/sj.bjc.6604249","article-title":"Multicentre prospective phase II trial of gefitinib for advanced non-small cell lung cancer with epidermal growth factor receptor mutations: Results of the West Japan Thoracic Oncology Group trial (WJTOG0403)","volume":"98","author":"Tamura","year":"2008","journal-title":"Br. J. Cancer"},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1093\/annonc\/mdm564","article-title":"Multicenter phase II trial of gefitinib first-line therapy followed by chemotherapy in advanced non-small-cell lung cancer (NSCLC): SAKK protocol 19\/03","volume":"19","author":"Rauch","year":"2008","journal-title":"Ann. Oncol."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"2380","DOI":"10.1056\/NEJMoa0909530","article-title":"Gefitinib or Chemotherapy for Non\u2013Small-Cell Lung Cancer with Mutated EGFR","volume":"362","author":"Maemondo","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.1200\/JCO.2005.05.1474","article-title":"Phase III Study of Erlotinib in Combination with Cisplatin and Gemcitabine in Advanced Non\u2013Small-Cell Lung Cancer: The Tarceva Lung Cancer Investigation Trial","volume":"25","author":"Gatzemeier","year":"2007","journal-title":"J. Clin. Oncol."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"2063","DOI":"10.1200\/JCO.2011.40.1315","article-title":"Randomized phase II trial of erlotinib alone or with carboplatin and paclitaxel in patients who were never or light former smokers with advanced lung adenocarcinoma: CALGB 30406 trial","volume":"30","author":"Wang","year":"2012","journal-title":"J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"3516","DOI":"10.1200\/JCO.2011.39.9782","article-title":"Randomized, Phase III Study of Gemcitabine or Erlotinib Maintenance Therapy Versus Observation, With Predefined Second-Line Treatment, After Cisplatin-Gemcitabine Induction Chemotherapy in Advanced Non\u2013Small-Cell Lung Cancer","volume":"30","author":"Chouaid","year":"2012","journal-title":"J. Clin. Oncol."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1093\/annonc\/mdf332","article-title":"Phase III randomised trial comparing paclitaxel\/carboplatin with paclitaxel\/cisplatin in patients with advanced non-small-cell lung cancer: A cooperative multinational trial","volume":"13","author":"Rosell","year":"2002","journal-title":"Ann. Oncol."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1056\/NEJMoa011954","article-title":"Comparison of Four Chemotherapy Regimens for Advanced Non\u2013Small-Cell Lung Cancer","volume":"346","author":"Schiller","year":"2002","journal-title":"N. Engl. J. Med."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1093\/annonc\/mdh015","article-title":"A phase II study of cisplatin and docetaxel administered as three consecutive weekly infusions for advanced non-small-cell lung cancer in elderly patients","volume":"15","author":"Ohe","year":"2004","journal-title":"Ann. Oncol."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"2589","DOI":"10.1056\/NEJMoa043623","article-title":"Vinorelbine plus Cisplatin vs. Observation in Resected Non\u2013Small-Cell Lung Cancer","volume":"352","author":"Winton","year":"2005","journal-title":"N. Engl. J. Med."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1093\/annonc\/mds578","article-title":"Randomized phase 2 trial on refinement of early-stage NSCLC adjuvant chemotherapy with cisplatin and pemetrexed versus cisplatin and vinorelbine: The TREAT study","volume":"24","author":"Kreuter","year":"2013","journal-title":"Ann. Oncol."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1093\/annonc\/mdl377","article-title":"Randomized phase III study of cisplatin plus irinotecan versus carboplatin plus paclitaxel, cisplatin plus gemcitabine, and cisplatin plus vinorelbine for advanced non-small-cell lung cancer: Four-Arm Cooperative Study in Japan","volume":"18","author":"Ohe","year":"2007","journal-title":"Ann. Oncol."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"iv119","DOI":"10.1093\/annonc\/mdx225","article-title":"Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"28","author":"Haanen","year":"2017","journal-title":"Ann. Oncol."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1159\/000437253","article-title":"Proteinuria in Patients with Solid Tumors Treated with Ramucirumab: A Systematic Review and Meta-Analysis","volume":"60","author":"ElHalawani","year":"2014","journal-title":"Chemotherapy"},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"2490","DOI":"10.3390\/toxins2112490","article-title":"Mechanisms of Cisplatin nephrotoxicity","volume":"2","author":"Miller","year":"2010","journal-title":"Toxins"},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1093\/ajcn\/83.4.735","article-title":"Cachexia: Pathophysiology and clinical relevance","volume":"83","author":"Morley","year":"2006","journal-title":"Am. J. Clin. Nutr."}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/22\/9\/4618\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T05:53:41Z","timestamp":1760162021000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/22\/9\/4618"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4,28]]},"references-count":92,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2021,5]]}},"alternative-id":["ijms22094618"],"URL":"https:\/\/doi.org\/10.3390\/ijms22094618","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,4,28]]}}}